Fears that Adriatic’s statistical survival wins would be clinically marginal haven’t materialised.

But toxicity could hold back Destiny-Breast06's ability to change clinical practice.

Meanwhile, Lilly gets in on the next-gen KRAS action.

Gilead came out swinging in second-line lung cancer, but it might have just whiffed.

The PD-1 x VEGF bispecific apparently bests Keytruda, but questions remain.

Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.

But will the FDA accept the surrogate endpoint used in ASC4First?

This weekend’s oncology conference will feature at least 30 different ADC projects.

Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.

Early release of petosemtamab’s ASCO data suggest that analysts’ bull case has been met.